Article Text

PDF
Sulfasalazine-induced immune thrombocytopenia
  1. L Cantarini1,
  2. I Tinazzi2,
  3. D Biasi2,
  4. A Fioravanti1,
  5. M Galeazzi1
  1. 1Rheumatology Unit, Department of Clinical Medicine and Immunological Sciences, University of Siena, Italy
  2. 2Department of Clinical and Experimental Medicine, University of Verona, Italy
  1. Correspondence to:
 Dr Ilaria Tinazzi
 Department of Clinical and Experimental Medicine, University of Verona, Pz.le Scuro,10 37134; Verona, Italy; ilariatinazzi{at}yahoo.it

Abstract

Sulfasalazine is a well established disease-modifying anti-rheumatic drug commonly used in the treatment of rheumatic disorders and inflammatory bowel disease. Sulfasalazine was generally well tolerated in clinical trials, the most frequently reported adverse effects being adverse gastrointestinal effects, headache, dizziness and rash; myelosuppression can also occur. We are now reporting the first case of autoimmune thrombocytosis following sulfasalazine treatment.

  • NSAIDs, non-steroidal, anti-inflammatory drugs
  • SLE, systemic lupus erythematosus
  • TNFα, tumour necrosis factor α

Statistics from Altmetric.com

Footnotes

  • Competing interests: None declared

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.